Report Sections

See All Reports

  • HP:0003002: Breast carcinoma
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0003002: Breast carcinoma

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (10)


    Name (Synonyms) Correlation
    drug782 Clinical Trial Matching Wiki 0.45
    drug625 COVID-19 convalescent plasma treatment Wiki 0.45
    drug628 COVID-19 e-package: Psychological wellbeing for healthcare workers Wiki 0.45
    Name (Synonyms) Correlation
    drug627 COVID-19 diagnostic test Wiki 0.45
    drug1319 Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC) Wiki 0.45
    drug3938 modification of the planned therapeutic management Wiki 0.45
    drug1771 Ketotifen 1 MG Wiki 0.45
    drug630 COVID-19 exposure Wiki 0.32
    drug623 COVID-19 convalescent plasma Wiki 0.20
    drug2732 Questionnaire Administration Wiki 0.13

    Correlated MeSH Terms (31)


    Name (Synonyms) Correlation
    D001943 Breast Neoplasms NIH 1.00
    D002583 Uterine Cervical Neoplasms NIH 0.63
    D002285 Carcinoma, Intraductal, Noninfiltrating NIH 0.45
    Name (Synonyms) Correlation
    D002277 Carcinoma NIH 0.45
    D002278 Carcinoma in Situ NIH 0.45
    D016889 Endometrial Neoplasms NIH 0.45
    D010051 Ovarian Neoplasms NIH 0.45
    D013274 Stomach Neoplasms NIH 0.45
    D014594 Uterine Neoplasms NIH 0.45
    D014625 Vaginal Neoplasms NIH 0.45
    D012878 Skin Neoplasms NIH 0.45
    D044584 Carcinoma, Ductal NIH 0.45
    D018270 Carcinoma, Ductal, Breast NIH 0.45
    D009423 Nervous System Neoplasms NIH 0.45
    D007680 Kidney Neoplasms NIH 0.45
    D016543 Central Nervous System Neoplasms NIH 0.45
    D014846 Vulvar Neoplasms NIH 0.45
    D005909 Glioblastoma NIH 0.45
    D008113 Liver Neoplasms NIH 0.45
    D007822 Laryngeal Neoplasms NIH 0.45
    D013736 Testicular Neoplasms NIH 0.45
    D002292 Carcinoma, Renal Cell NIH 0.32
    D004938 Esophageal Neoplasms NIH 0.32
    D012004 Rectal Neoplasms NIH 0.32
    D018281 Cholangiocarcinoma NIH 0.32
    D018358 Neuroendocrine Tumors NIH 0.32
    D010190 Pancreatic Neoplasms NIH 0.26
    D006258 Head and Neck Neoplasms NIH 0.26
    D003110 Colonic Neoplasms NIH 0.22
    D008175 Lung Neoplasms NIH 0.18
    D009369 Neoplasms, NIH 0.08

    Correlated HPO Terms (27)


    Name (Synonyms) Correlation
    HP:0030079 Cervix cancer HPO 0.63
    HP:0002896 Neoplasm of the liver HPO 0.45
    HP:0008069 Neoplasm of the skin HPO 0.45
    Name (Synonyms) Correlation
    HP:0012114 Endometrial carcinoma HPO 0.45
    HP:0100650 Vaginal neoplasm HPO 0.45
    HP:0100006 Neoplasm of the central nervous system HPO 0.45
    HP:0010788 Testicular neoplasm HPO 0.45
    HP:0030731 Carcinoma HPO 0.45
    HP:0009726 Renal neoplasm HPO 0.45
    HP:0012174 Glioblastoma multiforme HPO 0.45
    HP:0030416 Vulvar neoplasm HPO 0.45
    HP:0100615 Ovarian neoplasm HPO 0.45
    HP:0010784 Uterine neoplasm HPO 0.45
    HP:0100751 Esophageal neoplasm HPO 0.45
    HP:0004375 Neoplasm of the nervous system HPO 0.45
    HP:0006753 Neoplasm of the stomach HPO 0.45
    HP:0030075 Ductal carcinoma in situ HPO 0.45
    HP:0100605 Neoplasm of the larynx HPO 0.45
    HP:0005584 Renal cell carcinoma HPO 0.32
    HP:0100634 Neuroendocrine neoplasm HPO 0.32
    HP:0100743 Neoplasm of the rectum HPO 0.32
    HP:0030153 Cholangiocarcinoma HPO 0.32
    HP:0002894 Neoplasm of the pancreas HPO 0.26
    HP:0012288 Neoplasm of head and neck HPO 0.26
    HP:0003003 Colon cancer HPO 0.22
    HP:0100526 Neoplasm of the lung HPO 0.18
    HP:0002664 Neoplasm HPO 0.08

    Clinical Trials

    Navigate: Correlations   HPO

    There are 5 clinical trials


    1 SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

    NCT03452774
    Conditions
    1. Cancer, Metastatic
    2. Cancer
    3. Cancer of Pancreas
    4. Cancer of Liver
    5. Cancer of Stomach
    6. Cancer Liver
    7. Cancer of Rectum
    8. Cancer of Kidney
    9. Cancer of Esophagus
    10. Cancer of Cervix
    11. Cancer of Colon
    12. Cancer of Larynx
    13. Cancer, Lung
    14. Cancer, Breast
    15. Cancer, Advanced
    16. Cancer Prostate
    17. Cancer of Neck
    18. Cancer of Skin
    19. Neuroendocrine Tumors
    20. Carcinoma
    21. Mismatch Repair Deficiency
    22. BRCA Gene Rearrangement
    23. Non Hodgkin Lymphoma
    24. Leukemia
    25. Non Small Cell Lung Cancer
    26. Cholangiocarcinoma
    27. Glioblastoma
    28. Central Nervous System Tumor
    29. Melanoma
    30. Urothelial Carcinoma
    31. Bladder Cancer
    32. Ovarian Cancer
    33. Endometrial Cancer
    34. Testicular Cancer
    35. Breast Cancer
    36. COVID
    Interventions
    1. Other: Clinical Trial Matching
    MeSH:Carcinoma Glioblastoma Endometrial Neoplasms Neuroendocrine Tumors Cholangiocarcinoma Nervous System Neoplasms Central Nervous System Neoplasms Testicular Neoplasms Pancreatic Neoplasms Breast Neoplasms Lung Neoplasms Stomach Neoplasms Esop Esophageal Neoplasms Colonic Neoplasms Liver Neoplasms Uterine Cervical Neoplasms Rectal Neoplasms Kidney Neoplasms Carcinoma, Renal Cell Head and Neck Neoplasms Skin Neoplasms Laryngeal Neoplasms
    HPO:Breast carcinoma Carcinoma Cervical polyp Cervix cancer Cholangiocarcinoma Clear cell renal cell carcinoma Colon cancer Endometrial carcinoma Esophageal neoplasm Glioblastoma multiforme Neoplasm of head and neck Neoplasm of the breast Neoplasm of the central nervous system Neoplasm of the colon Neoplasm of the larynx Neoplasm of the liver Neoplasm of the lung Neoplasm of the nervous system Neoplasm of the pancreas Neoplasm of the rectum Neoplasm of the skin Neoplasm of the stomach Neuroendocrine neoplasm Papillary renal cell carcinoma Renal cell carcinoma Renal neoplasm Testicular neoplasm

    Primary Outcomes

    Description: CTE Accrual

    Measure: Proportion of patients Eligible for CTE versus Actual CTE

    Time: Through study completion, an average of 1 year

    Secondary Outcomes

    Description: OS

    Measure: Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis

    Time: 4 years

    Description: PFS

    Measure: Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis

    Time: 4 years

    Description: To identify barriers to accruals to clinical trials, as measured and reported by a questionnaire

    Measure: Identification of Barriers to CTE

    Time: Through study completion, an average of 1 year

    Description: To Analyze Individual Standard of Care Chemotherapy Utilization (nominal), across treatment lines (numeric); data will be combined and aggregated to report chemotherapy utilization rate (%).

    Measure: Real World Data Analytics

    Time: Through study completion, an average of 1 year

    Description: VTB Use Rate

    Measure: Virtual Tumor Board Utilization

    Time: Through study completion, an average of 1 year

    Description: Time to CTE

    Measure: Time from Intervention to Actual CTE (months)

    Time: Through study completion, an average of 1 year
    2 Potential Impact of the COVID -19 Pandemic on Financial Toxicity in Breast Cancer Surgical Patients: The Impact on Out of Pocket Costs, Lost Wages and Economic Strain

    This study investigates the impact of COVID-19 pandemic on out-of-pocket costs, lost wages, and unemployment in patients with breast cancer undergoing breast surgery. Post-mastectomy reconstructive patients are at high risk for financial toxicity (adverse effects of escalating health care cost on well-being). The goal of this study is to collect information about financial costs patients may have as a result of surgical treatment for cancer with or without breast reconstruction and to learn if COVID-19 affects patient costs of breast reconstruction. This may help researchers demonstrate the financial consequences of undergoing breast surgery.

    NCT04169542
    Conditions
    1. Breast Ductal Carcinoma In Situ
    2. COVID-19 Infection
    3. Hereditary Breast Carcinoma
    4. Invasive Breast Carcinoma
    Interventions
    1. Other: Questionnaire Administration
    MeSH:Carcinoma Breast Neoplasms Carcinoma in Situ Carcinoma, Ductal Carcinoma, Intraductal, Noninfiltrating Carcinoma, Ductal, Breast
    HPO:Breast carcinoma Carcinoma Ductal carcinoma in situ Neoplasm of the breast

    Primary Outcomes

    Description: Will be measured by the Comprehensive Score for financial Toxicity questionnaire. Summary statistics including mean, standard deviation, median, and range for continuous variables, and frequency count and percentage for categorical variables will be provided. Various subgroup analyses may occur. In these cases, continuous variables will be compared using the two-sample t-test and categorical variables will be compared using chi-squared test or Fisher's exact test. Multivariate regression analysis will be performed to account for confounding and to increase the robustness of any causal inference.

    Measure: Prevalence of financial toxicity

    Time: Up to 1 year after completion of study

    Secondary Outcomes

    Description: Summary statistics including mean, standard deviation, median, and range for continuous variables, and frequency count and percentage for categorical variables will be provided. Various subgroup analyses may occur. In these cases, continuous variables will be compared using the two sample t-test and categorical variables will be compared using chi-squared test or Fisher's exact test. Multivariate regression analysis will be performed to account for confounding and to increase the robustness of any causal inference.

    Measure: Correlation between economic disruption from coronavirus disease 2019 (COVID-19) and financial toxicity

    Time: Up to 1 year after completion of study

    Description: Will be assessed using the Short Form-12 survey. Summary statistics including mean, standard deviation, median, and range for continuous variables, and frequency count and percentage for categorical variables will be provided. Various subgroup analyses may occur. In these cases, continuous variables will be compared using the two-sample t-test and categorical variables will be compared using chi-squared test or Fisher's exact test. Multivariate regression analysis will be performed to account for confounding and to increase the robustness of any causal inference.

    Measure: Relationship between financial toxicity and patient reported quality of life

    Time: Up to 1 year after completion of study

    Description: Will be assessed using the Breast-Q survey. Summary statistics including mean, standard deviation, median, and range for continuous variables, and frequency count and percentage for categorical variables will be provided. Various subgroup analyses may occur. In these cases, continuous variables will be compared using the two-sample t-test and categorical variables will be compared using chi-squared test or Fisher's exact test. Multivariate regression analysis will be performed to account for confounding and to increase the robustness of any causal inference.

    Measure: Relationship between financial toxicity and patient reported satisfaction with breast reconstruction

    Time: Up to 1 year after completion of study
    3 Impact of the COVID-19 Pandemic on Changes in Therapeutic Strategies in Gynecological Oncology

    The current infection with the Coronavirus SARS-CoV-2 (COVID-19) is an exceptional health situation which requires an adaptation of our management practices in gynecological oncology. Data from the literature suggest that infection with Coronavirus is serious in subjects with cancer with a risk of severe form 5 times higher than that of the population without cancer and a risk of death multiplied by 8. In addition, the risk of infection would be 3 times greater in case of cancer. Faced with the COVID-19 epidemic, the investigator must organize themselves to ensure continuity in the treatment of patients with gynecological cancer but also adapt our practices in the management (CPR, teleconsultation, adaptation of treatment or even postponement of treatment). The objective of the High Council of Public Health is to be able to ensure adequate oncological care avoiding any potential loss of chance concerning the care of cancer: people affected must, despite the pandemic, have care allowing the same level of curability (localized cancers) or the same life expectancy (advanced cancers). This must be done by limiting as much as possible the impact on the organization of the service, the organization of patient follow-up and the psychological impact that these possible modifications could have. The hypotheses of our study are that the exceptional health situation linked to this pandemic leads to a change in the care of patients with gynecological cancer associated with a psychological impact and increased anxiety of patients during their care. Despite the extent of the pandemic, very little existing data makes it possible to define recommendations with a sufficient level of evidence.

    NCT04351139
    Conditions
    1. Gynecologic Cancer
    2. Breast Neoplasm Female
    3. Uterine Neoplasms
    4. Ovarian Neoplasms
    5. Uterine Cervical Neoplasms
    6. Vulvar Neoplasms
    7. Vaginal Neoplasms
    Interventions
    1. Other: modification of the planned therapeutic management
    MeSH:Neoplasms Breast Neoplasms Ovarian Neoplasms Uterine Cervical Neoplasms Uterine Neoplasms Vulvar Neoplasms Vaginal Neoplasms
    HPO:Breast carcinoma Cervical polyp Cervix cancer Neoplasm Neoplasm of the breast Ovarian neoplasm Uterine neoplasm Vaginal neoplasm Vulvar neoplasm

    Primary Outcomes

    Description: modification of the planned therapeutic management

    Measure: percentage of patients with a change in the planned therapeutic management (surgery, chemotherapy, radiotherapy, hormone therapy)

    Time: Day O
    4 An Expanded Access, Single-Arm, Multicenter Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic

    This single arm, multicenter study provides the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) administered at home by a home health nursing provider for patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer who are currently receiving pertuzumab (Perjeta) and trastuzumab (Herceptin) by intravenous administration (P+H IV). The main objective is to enable continuity of care during the COVID-19 pandemic. This study will enroll approximately 400 participants with HER2+ breast cancer who have completed concurrent chemotherapy with P+H IV and are currently receiving or will be receiving maintenance therapy with pertuzumab and trastuzumab. Participants will receive treatment every 3 weeks and continue treatment unless early cessation is necessary due to disease recurrence, disease progression, unacceptable toxicity or participant withdrawal. Only participants with HER2+ early breast cancer will receive PH FDC SC to complete 18 cycles of dual blockade, including the P+H IV they received prior to enrolling in this study. The Sponsor may decide to terminate the study when the COVID-19 pandemic is no longer a risk for this patient population.

    NCT04395508
    Conditions
    1. HER2-positive Breast Cancer
    Interventions
    1. Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC)
    MeSH:Breast Neoplasms
    HPO:Breast carcinoma Neoplasm of the breast

    5 Ketotifen: Novel Use as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy as Well as the Potential Beneficial Effects of Ketotifen in the Hypothetical Management of COVID-19

    The objective of our study was to evaluate the expected cardioprotective effects of ketotifen due to its activity as an iron-chelating agent previously uncovered by us in the in vitro chemical test which included in the study, when used in patients receiving anthracyclines for the treatment of breast cancer. The study was a randomized : , prospective controlled trial : , and the patients were identified by coded numbers to maintain privacy. Eligible patients (111) fulfilled the criteria. Control Group: 55 patients received their standard therapy (anthracycline-containing chemotherapy without ketotifen). Ketotifen Group: 56 patients received anthracycline-containing chemotherapy plus ketotifen as a cardioprotective agent. Ketotifen will be given orally as one tablet (1 mg/tablet) 3 times daily, before and during the chemotherapeutic cycle for 6 cycles of treatment. Blood samples were obtained from all patients, and echocardiography two times for each patient at baseline and after 6 months (EF%).

    NCT04435028
    Conditions
    1. Breast Cancer
    2. Iron Chelation
    Interventions
    1. Drug: Ketotifen 1 MG
    MeSH:Breast Neoplasms
    HPO:Breast carcinoma Neoplasm of the breast

    Primary Outcomes

    Description: the serum levels of LDH, CK-MB, troponin I, TIBC, ferritin, anti-cardiolipin IgG, and, iron were done

    Measure: prophylaxis effect of Ketotifen on patient's hearts during the treatment of anthracyclines

    Time: 6 months

    HPO Nodes


    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    Reports

    Data processed on January 01, 2021.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook